Literature DB >> 25916733

Chemoprophylaxis and vaccination in preventing subsequent cases of meningococcal disease in household contacts of a case of meningococcal disease: a systematic review.

L Telisinghe1, T D Waite1, M Gobin1, O Ronveaux2, K Fernandez2, J M Stuart3, R J P M Scholten4.   

Abstract

Household contacts of an index case of invasive meningococcal disease (IMD) are at increased risk of acquiring disease. In revising WHO guidance on IMD in sub-Saharan Africa, a systematic review was undertaken to assess the effect of chemoprophylaxis and of vaccination in preventing subsequent cases of IMD in household contacts following an index case. A literature search for systematic reviews identified a single suitable review on chemoprophylaxis in 2004 (three studies meta-analysed). A search for primary research papers published since 2004 on chemoprophylaxis and without a date limit on vaccination was therefore undertaken. There were 2381 studies identified of which two additional studies met the inclusion criteria. The summary risk ratio for chemoprophylaxis vs. no chemoprophylaxis (four studies) in the 30-day period after a case was 0·16 [95% confidence interval (CI) 0·04-0·64, P = 0·008]; the number needed to treat to prevent one subsequent case was 200 (95% CI 111-1000). A single quasi-randomized trial assessed the role of vaccination. The risk ratio for vaccination vs. no vaccination at 30 days was 0·11 (95% CI 0·01-2·07, P = 0·14). The results support the use of chemoprophylaxis to prevent subsequent cases of IMD in household contacts of a case. Conclusions about the use of vaccination could not be drawn.

Entities:  

Keywords:  Infectious disease control; Neisseria meningitides; meningococcal disease; meningococcus (N. meningitis); prevention

Mesh:

Substances:

Year:  2015        PMID: 25916733      PMCID: PMC9150978          DOI: 10.1017/S0950268815000849

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  25 in total

1.  Should we be doing more to prevent Group C meningococcal infection in school age children? How can we decide?

Authors:  A Round; S Palmer
Journal:  J Public Health Med       Date:  1999-03

Review 2.  Clinical practice. Prevention of meningococcal disease.

Authors:  Pierce Gardner
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

3.  Analysis of endemic meningococcal disease by serogroup and evaluation of chemoprophylaxis.

Authors: 
Journal:  J Infect Dis       Date:  1976-08       Impact factor: 5.226

4.  Prophylaxis for meningococcal disease.

Authors:  M S Artenstein
Journal:  JAMA       Date:  1975-03-10       Impact factor: 56.272

Review 5.  Effectiveness of antibiotics in preventing meningococcal disease after a case: systematic review.

Authors:  Bernadette Purcell; Susanne Samuelsson; Susan J M Hahné; Ingrid Ehrhard; Sigrid Heuberger; Ivonne Camaroni; André Charlett; James M Stuart
Journal:  BMJ       Date:  2004-06-05

6.  The detection of meningococcal household clusters and their prophylaxis in the changing epidemiological situation of invasive meningococcal disease in Poland, 2003-2006.

Authors:  P Stefanoff; M Rosinska; G Karczewski; A Zielinski
Journal:  Euro Surveill       Date:  2008-03-06

7.  Prevention of secondary cases of meningococcal disease in household contacts by vaccination.

Authors:  B M Greenwood; M Hassan-King; H C Whittle
Journal:  Br Med J       Date:  1978-05-20

Review 8.  Antibiotics for preventing meningococcal infections.

Authors:  Anca Zalmanovici Trestioreanu; Abigail Fraser; Anat Gafter-Gvili; Mical Paul; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2013-10-25

9.  Outcomes of meningococcal disease in adolescence: prospective, matched-cohort study.

Authors:  Jennie Borg; Deborah Christie; Pietro G Coen; Robert Booy; Russell M Viner
Journal:  Pediatrics       Date:  2009-03       Impact factor: 7.124

10.  Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews.

Authors:  Beverley J Shea; Jeremy M Grimshaw; George A Wells; Maarten Boers; Neil Andersson; Candyce Hamel; Ashley C Porter; Peter Tugwell; David Moher; Lex M Bouter
Journal:  BMC Med Res Methodol       Date:  2007-02-15       Impact factor: 4.615

View more
  4 in total

1.  Ciprofloxacin for contacts of cases of meningococcal meningitis as an epidemic response: study protocol for a cluster-randomized trial.

Authors:  Matthew E Coldiron; Gabriel Alcoba; Iza Ciglenecki; Matt Hitchings; Ali Djibo; Anne-Laure Page; Celine Langendorf; Rebecca F Grais
Journal:  Trials       Date:  2017-06-24       Impact factor: 2.279

2.  Single-dose oral ciprofloxacin prophylaxis as a response to a meningococcal meningitis epidemic in the African meningitis belt: A 3-arm, open-label, cluster-randomized trial.

Authors:  Matthew E Coldiron; Bachir Assao; Anne-Laure Page; Matt D T Hitchings; Gabriel Alcoba; Iza Ciglenecki; Céline Langendorf; Christopher Mambula; Eric Adehossi; Fati Sidikou; Elhadji Ibrahim Tassiou; Victoire De Lastours; Rebecca F Grais
Journal:  PLoS Med       Date:  2018-06-26       Impact factor: 11.069

3.  Analysis of a meningococcal meningitis outbreak in Niger - potential effectiveness of reactive prophylaxis.

Authors:  Matt D T Hitchings; Matthew E Coldiron; Rebecca F Grais; Marc Lipsitch
Journal:  PLoS Negl Trop Dis       Date:  2019-03-11

Review 4.  Occupational Health Update: Focus on Preventing the Acquisition of Infections with Pre-exposure Prophylaxis and Postexposure Prophylaxis.

Authors:  David J Weber; William A Rutala
Journal:  Infect Dis Clin North Am       Date:  2016-09       Impact factor: 5.982

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.